TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07175285: Prospective, Observational Study in Participants With Active Systemic Lupus Erythematosus (SLE) (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and At Least 2 Immunosuppressants

Sponsor: Bristol-Myers Squibb · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 223 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,070,000

Rescue Site Savings

+$1,380,000

Unlock Full NCT07175285 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07175285 Rescue Dossier →